Phase 4
Completed N=34
Pharmacogenomics of Antiplatelet Response
Source: ClinicalTrials.gov NCT02234427 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Differential Gene Expression |
77.1 | <0.000005 sig |
Eligibility Criteria
Inclusion Criteria
- 45-75 years
- GeneSTAR participant
- No personal History of Coronary Artery Disease
- Women who are post-menopausal
- Women who are using a reliable method of contraception, such as history of tubal ligation, IUD or taking OCP
Exclusion Criteria
- Taking aspirin prescribed by physician
- weight 160/95)
- History of gastrointestinal ulcer/bleeding
- Mental incompetence to make decision to participate.
Data sourced from ClinicalTrials.gov (NCT02234427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.